SOTHEMACAS:SOT +4.74%75 ROC (Joel Greenblatt) % is 29.53% as of Dec. 2025, which is 8% above its 10-year median of 27.42. GuruFocus rates CAS:SOT with a GF Score™ of 75/100 and a GF Value™ of MAD285.71 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 978 Drug Manufacturers companies, SOTHEMA ranks better than 73.31% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. SOTHEMA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 29.53%.
The historical rank and industry rank for SOTHEMA's ROC (Joel Greenblatt) % or its related term are showing as below:
CAS:SOT'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 21.81 Med: 27.42 Max: 35.86
Current: 28.8
During the past 13 years, SOTHEMA's highest ROC (Joel Greenblatt) % was 35.86%. The lowest was 21.81%. And the median was 27.42%.
CAS:SOT's ROC (Joel Greenblatt) % is ranked better than 73.31% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs CAS:SOT: 28.80
SOTHEMA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -3.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for SOTHEMA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS:SOT vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where SOTHEMA's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 29.53% mean?
SOTHEMA (CAS:SOT) has a ROC (Joel Greenblatt) % of 29.53% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on SOTHEMA and its competitors. This is near median its historical median of 27.42. Over the past decade, SOTHEMA's ROC (Joel Greenblatt) % has ranged from 21.81 to 35.86. According to the industry distribution chart, SOTHEMA ranks #261 out of 978 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is SOTHEMA's ROC (Joel Greenblatt) % too high?
SOTHEMA's current ROC (Joel Greenblatt) % of 29.53% is near median its 10-year median of 27.42. Over the past 10 years, this metric has ranged from a low of 21.81 to a high of 35.86. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. SOTHEMA's value of 29.53% is 157.9% above this industry median. Based on the distribution chart, SOTHEMA ranks #261 out of 978 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SOTHEMA has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #261 out of 978 companies for ROC (Joel Greenblatt) %. This puts SOTHEMA in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.45. SOTHEMA's value of 29.53% is 157.9% above this benchmark. Historically, SOTHEMA's own ROC (Joel Greenblatt) % has ranged from 21.81 to 35.86 over the past decade. While the company's 10-year median is 27.42 vs. the industry median of 11.45, SOTHEMA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOTHEMA's current ROC (Joel Greenblatt) % of 29.53% is 157.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on SOTHEMA and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current ROC (Joel Greenblatt) % is 29.53%, which is near median its own 10-year median of 27.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Significantly Overvalued. The stock's GF Value™ is MAD285.71, compared to a current price of MAD385.95 — trading 35.1% above its estimated fair value. The current ROC (Joel Greenblatt) % is 29.53%, which is near median its 10-year median of 27.42 and 157.9% above the Drug Manufacturers industry median of 11.45. SOTHEMA's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current ROC (Joel Greenblatt) % is 29.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD385.95 is trading 35.1% above its estimated GF Value™ of MAD285.71.
GuruFocus considers SOTHEMA to be Significantly Overvalued.
Key valuation signals for CAS:SOT:
ROC (Joel Greenblatt) %: 29.53% (near median its 10-year median of 27.42)
GF Value™: MAD285.71 vs. price of MAD385.95 (35.1% above fair value)
Industry Position: 157.9% above the Drug Manufacturers median (#261 of 978)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
75GF Score
Get the complete analysis for CAS:SOT
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
